D.P. Edwards reports Employer: Fresenius/NxStage Medical; Consultancy: Fresenius/NxStage; Honoraria: Ardelyx Pharma and NIH/NIDDK; Advisory or Leadership Role: Forum of ESRD Networks Patent Advisory Council (KPAC)–Co-Chairperson—Not Paid, Home Dialyzors United—Not Paid, Island Peer Review Organization Board of Directors Member—Paid, NIH/NIDDK Advisory Council—Paid, and Rogosin Institute Wellness Ambassadors Program—Paid; and Speakers Bureau: Fresenius/NxStage. D. Henner reports Consultancy: Outset Medical; Honoraria: Amgen and Outset Medical; and Speakers Bureau: Amgen and Outset Medical. K. Kalantar-Zadeh serves in the medical director teams of DaVita dialysis clinics affiliated to Harbor-UCLA. K. Kalantar-Zadeh also reports Consultancy: CSL/Vifor (ending 2023), Fresenius/Kabi (ending 2023), and GSK (ended 2023); The following have ended: Akebia (ended 2021), Ardelyx (ended 2022), AstraZeneca (ended 2022), CALLIDITAS (ended 2022), Daiichi Sankyo (ended 2021), Hikma (ended 2022), Horizon (ended 2021), Novo Nordisk (ended 2022), NxStage (ended 2022), Otsuka (ended 2021), Pfizer (ended 2022), Pharmacosmos (ended 2022), Sanofi (ended 2022), and Travere (ended 2022); Research Funding: Lundquist Institute at Harbor-UCLA, NIH NIDDK, and VA ORD; Honoraria: CSL/Vifor, Fresenius/Kabi, and GSK, ending in 2023; Honoraria by other companies listed under Consultancy ended by 2022, Note that the AHRQ (Federal Government) honoraria will continue through 2024 for study section appointment; Patents or Royalties: PATENTS: Prognostic assays for maintenance hemodialysis patients 2019 (Harbor-UCLA/Lundquist); Methods of treating renal disease 2021 (University of California Irvine, UCI); and Speakers Bureau: CSL/Vifor, Fresenius/Kabi, and GSK all ending in 2023; Speaker program from all other companies listed under Consultancy ended by 2022. D.L. Landry reports Advisory or Leadership Role: Chair for the Medical Advisory Council at the National Forum of ESRD Networks as well as Chair for the Medical Review Board for ESRD Network 1, receives no financial compensation for either position. D.L. Landry also serves as a medical director for Fresenius Kidney Care dialysis clinics. D.A. Molony reports Honoraria: AstraZeneca, Fresenius Medical Care, and Medtronics; Advisory or Leadership Role: ESRD Network 14 Board of Directors and Forum of ESRD Networks; Speakers Bureau: AstraZeneca, Fresenius Medical, and Medtronics; and Other Interests or Relationships: Forum of ESRD Networks—Past-President Board of Directors; Medical Advisory Council—Forum of ESRD Networks, Medical Review Board, Past-Chair—ESRD Network 14 of Texas. P. Yerram reports Consultancy: GSK; Ownership Interest: Sensionics; Research Funding: Ablative Solutions, AstraZeneca, Bayer, CareDx, and CSL Behring; Honoraria: CSL Vifor, GSK, and Travere Therapeutics; Advisory or Leadership Role: Unpaid: MOKP advisory council member, National Forum of ESRD Networks BOD member, and Vice chair—National Forum of ESRD Networks Medical Director Advisory council (MAC); Paid: Qsource BOD member; and Speakers Bureau: GSK. All authors have affiliations with one or more ESRD Network organizations.